Literature DB >> 1068530

The pathogenesis and clinical patterns of blastic crisis of chronic myeloid leukemia.

D R Boggs.   

Abstract

Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The time of its onset appears to be a random phenomenon, varying from a probable coincidence occurrence with the onset of CML to more than a decade after onset of the chronic phase. In most patients the diagnosis is obvious as very immature cells are found to be the predominant cell in blood and marrow. However, in some, the onset is fairly subtle and the diagnosis of the syndrome will be dependent upon ancillary clinical and laboratory clues supplementing morphologic appearance of the blood and bone marrow. The same spectrum of morphological cell types is observed in blast crisis as is observed in acute myeloid leukemia. The predominant cells usually are myeloblasts and promyelocytes but may be immature monocytes, myelomonocytes, proerythroblasts, or immature megakaryocytes. These and other findings imply that the defect resides in the pluripotent hematopoietic stem cell. It is possible, but by no means proven, that lymphoblastic conversion also may occur. Therapy of blast crisis is quite unsatisfactory but clearly is of benefit in some patients.

Entities:  

Mesh:

Year:  1976        PMID: 1068530

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  6 in total

1.  Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.

Authors:  Tomonori Nakazato; Noriyoshi Iriyama; Michihide Tokuhira; Maho Ishikawa; Eriko Sato; Tomoiku Takaku; Kei-Ji Sugimoto; Hiroyuki Fujita; Isao Fujioka; Yuta Kimura; Yoshinobu Aisa; Eisaku Iwanaga; Norio Asou; Masahiro Kizaki; Yoshihiro Hatta; Norio Komatsu; Tatsuya Kawaguchi
Journal:  Med Oncol       Date:  2018-05-30       Impact factor: 3.064

2.  Immunologic diagnosis and monitoring of human acute leukemias: a review.

Authors:  M Maheu; M A Baker; J A Falk; R N Taub
Journal:  Am J Pathol       Date:  1981-04       Impact factor: 4.307

3.  Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia.

Authors:  N Gunnarsson; M Höglund; L Stenke; S Wållberg-Jonsson; F Sandin; M Björkholm; A Dreimane; M Lambe; B Markevärn; U Olsson-Strömberg; H Wadenvik; J Richter; A Själander
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

4.  Translocations (4p+; 6q-) and (12q-; Xp+) in blastic phase of a Ph1-positive chronic myeloid leukemia.

Authors:  S Suciu; E Marinca; F Bornuz; M Crisan; L Petrov; E Rădulescu
Journal:  Blut       Date:  1984-10

5.  Lymph node involvement in chronic neutrophilic leukemia. An immunohistochemical study.

Authors:  H Nakamine; K Hirano; M Tsujimoto; E Nishino; T Takenaka; J Maeda; Y Muragaki; A Ooshima; H Hara
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1988

6.  A new approach to the evolution of the blastic crisis from chronic myelocytic leukemia: dynamic interplay of cellular alterations and a changing microenvironment.

Authors:  Z Grossman
Journal:  EMBO J       Date:  1986-04       Impact factor: 11.598

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.